Asset Details
Do you wish to reserve the book?
Comparative analysis of fourteen COVID-19 vaccine injury compensation systems and claim approval rates
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Comparative analysis of fourteen COVID-19 vaccine injury compensation systems and claim approval rates
Do you wish to request the book?
Comparative analysis of fourteen COVID-19 vaccine injury compensation systems and claim approval rates
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Comparative analysis of fourteen COVID-19 vaccine injury compensation systems and claim approval rates
2025
Overview
No-fault vaccine injury compensation schemes provide financial redress for adverse effects from vaccines without establishing fault. Due to the rapid vaccine development and distribution, these programs are crucial for vaccinees during the COVID-19 pandemic. Investigating the performance differences of these schemes worldwide and finding a more balanced approach is essential to responses to future pandemics.
This study examines the structure and effectiveness of 14 no-fault vaccine injury compensation schemes, analyzing data on approval rates for COVID-19 vaccine injury claims. Data sources include government reports and academic studies to compare diverse operational models and funding sources.
This study included 167,532 COVID-19 vaccine injury compensation applications, with up to 137,076 claims reviewed and up to 38,658 approved, incorporating both exact and approximate official numbers. Approval rates for the reviewed claims vary widely across jurisdictions, with Japan (74.29 %) having the highest rates, and the United States (3 %) and the United Kingdom (2.64 %) the lowest. The median approval rate across all 14 jurisdictions is 26.76 %, between South Korea's 26.09 % and France's 27.42 %. These variations reflect diverse standards and policies. No clear correlation exists between funding sources and approval rates. For example, government-funded schemes in France and Japan show higher approval rates, while similar models in the United States and the United Kingdom have low rates. In New Zealand and other countries with broader medical compensation schemes, approval rates are higher than the international median.
Governments may adopt more flexible standards to redress vaccine injuries by referring to international practices and the latest medical evidence. High-approval-rate countries offer insights into inclusive criteria, while low-approval-rate countries may need to reassess stringent criteria. Middle-ground countries could incorporate new medical findings to refine standards, ensuring equitable outcomes for those affected by vaccine injuries.
Publisher
Elsevier Ltd,Elsevier Limited
